Interferon-Lambda as a Potential Therapeutic Agent in Cancer Treatment
- 1 August 2010
- journal article
- review article
- Published by Mary Ann Liebert Inc in Journal of Interferon & Cytokine Research
- Vol. 30 (8), 597-602
- https://doi.org/10.1089/jir.2010.0058
Abstract
The discovery that type I interferon (IFN-α/β) inhibited tumor cell growth was welcomed initially with great excitement as it rapidly became a U.S. Food and Drug Administration–approved drug to treat several forms of cancer. In time, this enthusiasm diminished as severe toxicity associated with IFN-α administration, resistance to the therapy, or less than optimal responses became evident in cancer patients, thus restricting its clinical use and reducing its potential as an anticancer drug. The recent discovery of a third type of IFN [IFN-λ/interleukin (IL)-29/IL-28], which shares the same biological properties of type I IFNs, opens the door for evaluating the therapeutic potential of IFN-λ as it uses a distinct receptor complex whose expression, unlike type I IFN receptors, is restricted to cells of specific lineage. It is unclear whether the mechanism by which type III IFNs restrict tumor cell proliferation is different or the same from the one utilized by type I IFN. Nevertheless, accumulating evidence as described in this review suggests that, in contrast to IFN-α therapy, IFN-λ therapy could be less toxic and suitable for certain types of malignancies as not all cells are responsive to this cytokine.Keywords
This publication has 36 references indexed in Scilit:
- p21 in cancer: intricate networks and multiple activitiesNature Reviews Cancer, 2009
- The Role of Genomic Data in the Discovery, Annotation and Evolutionary Interpretation of the Interferon-Lambda FamilyPLOS ONE, 2009
- Human interferon-λ3 is a potent member of the type III interferon familyGenes & Immunity, 2008
- Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytesHepatology, 2006
- Lambda Interferon (IFN-λ), a Type III IFN, Is Induced by Viruses and IFNs and Displays Potent Antiviral Activity against Select Virus Infections In VivoJournal of Virology, 2006
- IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expressionAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2005
- Role of the Interleukin (IL)-28 Receptor Tyrosine Residues for Antiviral and Antiproliferative Activity of IL-29/Interferon-λ1Published by Elsevier BV ,2004
- The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chainJournal of Leukocyte Biology, 2004
- Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3Biochemical Journal, 2003
- Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosisApoptosis, 2003